Cel-Sci (CVM) vs Metagenomi Therapeutics (MGX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Metagenomi Therapeutics (MGX) has outperformed Cel-Sci (CVM) over the past year, losing 62.6% versus a loss of 80.7%. Metagenomi Therapeutics is the larger company by market cap ($21.4 million vs $21.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CVM | MGX |
|---|---|---|
| Share price | $1.21 | $0.565 |
| Market cap | $21.28M | $21.36M |
| 1-day change | -17.69% | -7.95% |
| YTD return | -77.00% | -65.12% |
| 1-year return | -80.67% | -62.58% |
| 5-year return | -99.61% | — |
| EPS (TTM) | $-1.69 | $-2.50 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $25.21M |
| Revenue growth (YoY) | — | -51.79% |
| Net income (latest FY) | $-25.41M | $-87.87M |
| Operating margin | — | -380.85% |
| Net margin | — | -348.54% |
| 52-week high | $7.80 | $1.87 |
| 52-week low | $0.89 | $0.562 |
| Distance from 52-week high | -84.49% | -69.79% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +933.06% | +1138.94% |
| Average volume | 231.46K | 163.21K |
| Shares outstanding | 17.59M | 37.81M |
| Employees | — | 113 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MGX has outperformed CVM by 18.1 percentage points over the past year.
About Cel-Sci
CVM stock →CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
About Metagenomi Therapeutics
MGX stock →Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 113 employees
CVM vs MGX FAQ
Which is bigger, Cel-Sci or Metagenomi Therapeutics?
Metagenomi Therapeutics (MGX) is larger, with a market capitalization of $21.36M compared with $21.28M for Cel-Sci (CVM).
Which stock has performed better over the past year, CVM or MGX?
MGX returned -62.58% over the past 12 months, compared with -80.67% for CVM (price return, excluding dividends). Past performance does not predict future results.
Are Cel-Sci and Metagenomi Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.